Journal
APL MATERIALS
Volume 8, Issue 10, Pages -Publisher
AIP Publishing
DOI: 10.1063/5.0025211
Keywords
-
Funding
- National Key R&D Program of China [2019YFA0110600]
- National Natural Science Foundation of China [81970916, 81671031]
Ask authors/readers for more resources
Nucleic acid therapy has played a promising role in the treatment of many diseases, such as cancer, infections, immune diseases, and neurodegenerative diseases. However, its application is still limited mainly because of poor cell-entry performance and low resistance to in vivo degradation. Tetrahedral framework nucleic acids (tFNAs) have shown potential in delivering low-molecular-weight drugs owing to their stability, biocompatibility, cell-entry performance, and flexible drug-loading ability. In particular, tFNAs can successfully deliver oligonucleotide drugs with improved effects and co-deliver oligonucleotide drugs with other drugs for synergistic effects. In this review, the recent progress on tFNA-based delivery of oligonucleotide drugs is outlined by single delivery systems-through sequence extension and complementation, and co-delivery systems-through multiple sequence extension, drug-DNA interactions, and specific binding. Furthermore, the current limitations and future developments of tFNA-based delivery of oligonucleotide drugs are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available